Pacific Biosciences of California, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Pacific Biosciences of California, Inc. (PACB) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- Pacific Biosciences of California, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $664.00K, a 26.55% decline year-over-year.
- Pacific Biosciences of California, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $849.00K, a 32.51% decline year-over-year.
- Pacific Biosciences of California, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $894.00K, a 28.65% decline year-over-year.
- Pacific Biosciences of California, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $921.00K, a 81.78% decline year-over-year.
- Pacific Biosciences of California, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $3.98M, a 67.31% decline from fiscal 2024.
- Pacific Biosciences of California, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $12.16M, a 78.63% increase from fiscal 2023.
- Pacific Biosciences of California, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $6.81M, a 1.66% decline from fiscal 2022.
- Pacific Biosciences of California, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $6.92M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $664.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.51M 10-Q · filed 2026-08-06 | $2.41M derived: sum of 3 quarters · filed 2026-08-06 | $3.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $849.00K 10-Q · filed 2026-05-08 | $1.74M derived: sum of 2 quarters · filed 2026-05-08 | $2.66M derived: sum of 3 quarters · filed 2026-05-08 | $3.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $894.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.81M derived: sum of 2 quarters · filed 2026-02-25 | $2.72M derived: sum of 3 quarters · filed 2026-08-06 | $3.98M 10-K · filed 2026-02-25 |
| 2025-09-30 | $921.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.82M derived: sum of 2 quarters · filed 2026-08-06 | $3.08M 10-Q · filed 2025-11-06 | $4.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $904.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.16M 10-Q · filed 2026-08-06 | $3.42M derived: sum of 3 quarters · filed 2026-08-06 | $8.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.26M 10-Q · filed 2026-05-08 | $2.51M derived: sum of 2 quarters · filed 2026-05-08 | $7.57M derived: sum of 3 quarters · filed 2026-05-08 | $11.50M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.31M derived: sum of 2 quarters · filed 2026-02-25 | $10.24M derived: sum of 3 quarters · filed 2026-02-25 | $12.16M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.99M derived: sum of 2 quarters · filed 2025-11-06 | $10.91M 10-Q · filed 2025-11-06 | $12.78M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.86M 10-Q · filed 2025-08-07 | $7.73M derived: sum of 3 quarters · filed 2026-02-25 | $9.34M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $1.92M 10-Q · filed 2025-05-12 | $3.79M derived: sum of 2 quarters · filed 2026-02-25 | $5.40M derived: sum of 3 quarters · filed 2026-02-25 | $7.20M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.48M derived: sum of 2 quarters · filed 2026-02-25 | $5.28M derived: sum of 3 quarters · filed 2026-02-25 | $6.81M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.41M derived: sum of 2 quarters · filed 2024-11-12 | $4.94M 10-Q · filed 2024-11-12 | $6.71M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $3.33M 10-Q · filed 2024-08-09 | $5.10M derived: sum of 3 quarters · filed 2025-03-17 | $6.84M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $1.53M 10-Q · filed 2024-05-09 | $3.30M derived: sum of 2 quarters · filed 2025-03-17 | $5.04M derived: sum of 3 quarters · filed 2025-03-17 | $6.76M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $3.51M derived: sum of 2 quarters · filed 2025-03-17 | $5.23M derived: sum of 3 quarters · filed 2025-03-17 | $6.92M 10-K · filed 2025-03-17 |
| 2022-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $3.46M derived: sum of 2 quarters · filed 2023-11-03 | $5.15M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $3.41M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $1.70M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |